To determine if prophylactic supplementation with B. lactis HN019 reduces the risk of developing physician- and laboratory-confirmed influenza infection at any time during the 12-week supplementation period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
426
B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks
Placebo sachet, consumed once per day for 12 weeks
Clinical Research of South Florida
Coral Gables, Florida, United States
RECRUITINGRemedica, LLC
Rochester, Michigan, United States
RECRUITINGInfluenza infection
Incidence of physician- and laboratory-confirmed influenza infection at any time during the 12-week supplementation period
Time frame: 12 weeks
Symptom duration
Time frame: 12 weeks
Symptom severity
Time frame: 12 weeks
Adverse event incidence
The proportion of subjects that reports at least one adverse event (regardless of cause) during the study
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.